biostudies-literatureAzizi MBarts Charity651-661https://www.ebi.ac.uk/biostudies/studies/S-EPMC9975904biostudies-literatureUnknown329(8)<h4>Importance</h4>Two initial sham-controlled trials demonstrated that ultrasound renal denervation decreases blood pressure (BP) in patients with mild to moderate hypertension and hypertension that is resistant to treatment.<h4>Objective</h4>To study the efficacy and safety of ultrasound renal denervation without the confounding influence of antihypertensive medications in patients with hypertension.<h4>Design, setting, and participants</h4>Sham-controlled, randomized clinical trial with patients and outcome assessors blinded to treatment assignment that was conducted between January 14, 2019, and March 25, 2022, at 37 centers in the US and 24 centers in Europe, with randomization stratified by center. Patients aged 18 years to 75 years with hypertension (seated office systolic BP [SBP] JAMAEndovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.PMC9975904MGU0386Stephan JAbraham ABiswas SHalliday IDelsart PAbraham JLutz MRedfors BLoening AWillitts AChami YJain APetzold MSchindler JRenard KHart AZentko SRoberson MRamirez JRamirez HLafeber MHall JMcClure CKLevy TKulenthiran SBranche MTouchton AFintel DWachter ARisher SKirtane AJRuiter APascal SDohad SLea JWeil JKrathen CDogan OBriki RBasile JEhret GBatres CEnglish LPapadopoulos PAzizi MWeber MAPasala TBagnall ALunardi MTulik LNicholson TBhatia KKannenkeril DLoader DRADIANCE II Investigators and CollaboratorsTutor ICohen DBunte MBertolet BKrishnaswamy AChertow GReimer PDrilling PKoch CNix SMaire FThompson EMcMeans ASalazer TTuohy EAl-Janabi FCohn Jde Hemptinne QSharp ASPAkinapelli AVeis JLewis LButtner MMendelsohn FFishman RIyer SGAlbright MJones LRommel KPHennicaux JTeklinski ASaxena MXaplanteris PMerlin CJohnson KHashim HArakelian PZongo OAnderson RPetzsche UPadmanabhan SDagkonakis NReeve-Stoffer HDi Ponio-Voit IDevireddy CChandra VJackson LCawthon TSayer JNeubauer RHatchcock ERedman EJackson RKats LBajzer CHausberg MKodoth VAgdirlioglu TDobretz KBalawon ANeumann BWilson PGlynn NHeinritz UWeinberg MChugh ABoros MGo BGollapudi RSobieszczyk PDeRamus SLauder LHorler SSapoval MGoldman JGaudissard JDauerman HSanghvi KMokrzycki MMartin SEllam TTecklenburg ATopham CEdwards SGosse PLanders DBloch MJHector GBent CCanino PMullin CKahan TPeterson RVefali HLeech APacella JIbebuogu ULefebvre PGallego LZagoria RMunson TLaffin LBae RBernardo NLindsey JFisher NDLClaude LLivrozet MBenzuly KReilly JPTran AGulliver ARegrag AMcCurry TAdams KHsi DDoulton TMuldoon MHinderliter AGarasic JPortnay EFengler KAllen MSpiro NScholl TZeijen VAdams TCremer AYang YMSommeville CKhuddus MMathur AStarkey EGiri JEndres-Frohlich KKobayashi TFlack JBrantley HDaemen JHuang PFerdinande BPaquet VHodges EPaparello JKhaliq AWade WWang YSingh SMullaney STodoran TMMahfoud FPratt KIglesias JFRadhakrishnan JSchmieder REBertrand FEttl UGainer JThackeray LHinrichs RBeohar NHafiz AMLaster SJenkins JSCoen Evan Ramshorst JFiebach ASkeik NSchmid ALeBlanc JDas NHamann FAbetu YStouffer RFong PGaravito CKollner TAlhmoudi AFiebach MCrook SHarrison MNaidu SPenning ARogers KLobo MDUllery SBridgett VRobinson NWhitman DStijleman IKing DCushman WSharif FAwkar ALurz PPalmer CRader FfalseEndovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.<h4>Importance</h4>Two initial sham-controlled trials demonstrated that ultrasound renal denervation decreases blood pressure (BP) in patients with mild to moderate hypertension and hypertension that is resistant to treatment.<h4>Objective</h4>To study the efficacy and safety of ultrasound renal denervation without the confounding influence of antihypertensive medications in patients with hypertension.<h4>Design, setting, and participants</h4>Sham-controlled, randomized clinical trial with patients and outcome assessors blinded to treatment assignment that was conducted between January 14, 2019, and March 25, 2022, at 37 centers in the US and 24 centers in Europe, with randomization stratified by center. Patients aged 18 years to 75 years with hypertension (seated office systolic BP [SBP] 2023-01-01T00:00:00Z2023 Feb2026-06-17T06:40:51.628Z2025-04-04T21:02:06.568ZS-EPMC99759043685325010.1001/jama.2023.0713